Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Cipla
Fish and Richardson
McKesson
Express Scripts
Moodys
Argus Health
Medtronic
McKinsey

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for Patent: RE38912

« Back to Dashboard

Which drugs does patent RE38912 protect, and when does it expire?

Patent RE38912 protects SPIRIVA and is included in one NDA.

Protection for SPIRIVA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has one hundred and seven patent family members in forty-nine countries.
Summary for Patent: RE38912
Title: Process for preparing powder formulations
Abstract:The invention relates to a new process for producing powdered preparations for inhalation.
Inventor(s): Walz; Michael (Bingen, DE), Boeck; Georg (Mainz, DE)
Assignee: Boehringer Ingelheim Pharma KG (Ingelheim, DE)
Application Number:10/766,748
Patent Claim Types:
see list of patent claims
Composition; Process; Device; Compound;

Drugs Protected by US Patent RE38912

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Boehringer Ingelheim SPIRIVA tiotropium bromide POWDER;INHALATION 021395-001 Jan 30, 2004 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: RE38912

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany100 50 635Oct 12, 2000
Germany101 38 022Aug 10, 2001

Non-Orange Book US Patents Family Members for Patent RE38912

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,585,959 Process for preparing powder formulations ➤ Try a Free Trial
7,070,800 Inhalable powder containing tiotropium ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent RE38912

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1712 ➤ Try a Free Trial
Argentina 031819 ➤ Try a Free Trial
Argentina 034166 ➤ Try a Free Trial
Austria 275391 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Dow
US Department of Justice
Harvard Business School
Baxter
US Army
Mallinckrodt
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.